Anumana, Pfizer collaborate on AI-based detection of cardiovascular disease
Related Articles
Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod
Bioworld: Anumana Inc. has garnered a U.S. FDA breakthrough device designation for its artificial intelligence (AI)-powered electrocardiogram-based algorithm for early identification of cardiac amyloidosis. The ECG-AI detection algorithm is the…June 21, 2023
Mayo Clinic AI algorithm proves effective at spotting early-stage heart disease in routine EKG data
FIERCE Biotech: An algorithm developed by the Mayo Clinic can significantly increase the number of cases of low ejection fraction caught in its earliest stages, when it’s still most treatable,…May 09, 2022
Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease
Diagnostic and Interventional Cardiology: Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosisDecember 20, 2022
Fierce Medtech’s 2022 Fierce 15
Fierce Medtech: Since its humble beginnings back in 2012, the Fierce 15 has made a point of spotlighting the most exciting startups in medtech—those not only challenging the limits of…March 20, 2023